Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels

NCT01344447 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01344447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2011
Completion date
May 28, 2014
Enrollment
479 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

carotid stenosis